Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss for the year	$ (8,320)	$ (14,649)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of property and equipment	55	60
Amortization of clinical trial deposit		3,225
Change in fair value of milestone liability	20	3
Restricted stock units and shares issued for services	171	200
Stock option expense	607	1,490
Changes in operating assets and liabilities
Prepaid expenses, deposits and other	246	371
Clinical trial deposits	870	(1,700)
Accounts payable and accrued liabilities	(577)	(442)
Related party payables	(248)	(423)
Net cash used in operating activities	(7,176)	(11,865)
Cash flows from investing activities
Purchase of equipment	(20)	(232)
Net cash used in investing activities	(20)	(232)
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	10,576	1,903
Payment of prior year issuance costs		(43)
Series A preferred cash dividend	(6)	(8)
Net cash provided by financing activities	10,570	1,852
Increase (decrease) in cash and cash equivalents	3,374	(10,245)
Cash and cash equivalents – beginning of year	1,535	11,780
Cash and cash equivalents – end of year	$ 4,909	$ 1,535